Enanta Pharmaceuticals Inc ENTA
Institutional shares held
21.1 Million
4.8K
calls
4.6K
puts
Total value of holdings
$169M
$38K
calls
$36K
puts
Market Cap
$166M
20,724,900
Shares Out.
Institutional ownership
101.72%
# of Institutions
110
We take great care to ensure that the data presented and summarized in this overview for ENANTA PHARMACEUTICALS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ENTA
View all-
Farallon Capital Management LLC San Francisco, CA2.11MShares$16.9 Million0.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.98MShares$15.9 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.85MShares$14.8 Million0.0% of portfolio
-
Krensavage Asset Management, LLC New York, NY1.5MShares$12 Million8.7% of portfolio
-
Morgan Stanley New York, NY1.1MShares$8.82 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY1MShares$8 Million0.17% of portfolio
-
Marshall Wace, LLP London, X0851KShares$6.81 Million0.01% of portfolio
-
Acadian Asset Management LLC Boston, MA849KShares$6.8 Million0.03% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT786KShares$6.28 Million0.69% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny731KShares$5.85 Million0.0% of portfolio
Latest Institutional Activity in ENTA
Top Purchases
Top Sells
About ENTA
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
Insider Transactions at ENTA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 06
2024
|
Tara Lynn Kieffer Chief Product Strategy Officer |
SELL
Open market or private sale
|
Direct |
2,283
-7.23%
|
$18,264
$8.06 P/Share
|
|
Dec 06
2024
|
Brendan Luu Chief Business Officer |
SELL
Open market or private sale
|
Direct |
2,283
-5.96%
|
$18,264
$8.06 P/Share
|
|
Dec 06
2024
|
Yat Sun Or Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,591
-0.7%
|
$20,728
$8.06 P/Share
|
|
Dec 06
2024
|
Scott T. Rottinghaus Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
866
-4.61%
|
$6,928
$8.06 P/Share
|
|
Dec 06
2024
|
Jay R. Luly President and CEO |
SELL
Open market or private sale
|
Direct |
5,142
-0.64%
|
$41,136
$8.06 P/Share
|
|
Dec 06
2024
|
Paul J Mellett Chief Fin. & Admin Officer |
SELL
Open market or private sale
|
Direct |
2,591
-2.75%
|
$20,728
$8.06 P/Share
|
|
Dec 01
2024
|
Brendan Luu Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
753
-1.93%
|
$6,024
$8.6 P/Share
|
|
Dec 01
2024
|
Yat Sun Or Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,595
-0.43%
|
$12,760
$8.6 P/Share
|
|
Dec 01
2024
|
Tara Lynn Kieffer Chief Product Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
753
-2.33%
|
$6,024
$8.6 P/Share
|
|
Dec 01
2024
|
Paul J Mellett Chief Fin. & Admin Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,595
-1.66%
|
$12,760
$8.6 P/Share
|
|
Dec 01
2024
|
Jay R. Luly President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,829
-0.47%
|
$30,632
$8.6 P/Share
|
|
Aug 08
2024
|
Scott T. Rottinghaus Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,466
-7.24%
|
$17,592
$12.73 P/Share
|
|
Jul 15
2024
|
Scott T. Rottinghaus Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,375
-19.84%
|
$91,375
$17.08 P/Share
|
|
Jul 15
2024
|
Scott T. Rottinghaus Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,375
+16.56%
|
$43,000
$8.99 P/Share
|
|
Jul 12
2024
|
Scott T. Rottinghaus Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,271
-9.47%
|
$34,065
$15.04 P/Share
|
|
Jul 11
2024
|
Scott T. Rottinghaus Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,299
-15.2%
|
$64,485
$15.07 P/Share
|
|
Jun 17
2024
|
Tara Lynn Kieffer Chief Product Strategy Officer |
SELL
Open market or private sale
|
Direct |
7,266
-18.35%
|
$87,192
$12.33 P/Share
|
|
Feb 26
2024
|
Nathaniel S. Gardiner Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,187
+6.41%
|
$41,496
$8.99 P/Share
|
|
Feb 12
2024
|
Tara Lynn Kieffer Chief Product Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
973
-2.4%
|
$11,676
$12.41 P/Share
|
|
Feb 12
2024
|
Tara Lynn Kieffer Chief Product Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,320
+7.56%
|
-
|
Last 12 Months Summary
Buy / Acquisition
35.5K
Shares
From
9
Insiders
| Grant, award, or other acquisition | 24.9K shares |
|---|---|
| Exercise of conversion of derivative security | 10.6K shares |
Sell / Disposition
67.6K
Shares
From
14
Insiders
| Payment of exercise price or tax liability | 17.3K shares |
|---|---|
| Open market or private sale | 50.3K shares |